Kalytera Therapeutics

kalytera therapeutics (tsxv: kaly) is pioneering the development of a next generation of cannabinoid therapeutics. kalytera is focused first on developing a new class of proprietary cannabidiol (“cbd”) therapeutics. cbd is a remarkable compound that has shown activity against a number of pharmacological targets. however, there are limitations associated with natural cbd, including its poor oral bioavailability. kalytera’s lead program includes four phase 2 clinical studies evaluating cbd in the prevention and treatment of graft versus host disease (“gvhd”). kalytera is also developing innovative cbd formulations and prodrugs in an effort to overcome the limitation of cbd’s poor oral bioavailability and to target delivery of cbd to specific disease sites within the body. kalytera intends to file composition of matter and method of use patents covering its novel cbd formulations and prodrugs, with the goal of limiting future competition.